Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Avastin and Lucentis: what do patients know? A prospective questionnaire survey.

Manna A, Oyede O, Ning B, Yang Y, Narendran N.

JRSM Short Rep. 2013 Jul 30;4(9):2042533313484146. doi: 10.1177/2042533313484146. eCollection 2013.

2.
3.

Ranibizumab (Lucentis) versus Bevacizumab (Avastin) for the Treatment of Age-Related Macular Degeneration: An Economic Disparity of Eye Health.

Moreno TA, Kim SJ.

Semin Ophthalmol. 2016;31(4):378-84. doi: 10.3109/08820538.2016.1154174. Epub 2016 Apr 26. Review.

PMID:
27116030
4.

Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results.

Berg K, Hadzalic E, Gjertsen I, Forsaa V, Berger LH, Kinge B, Henschien H, Fossen K, Markovic S, Pedersen TR, Sandvik L, Bragadóttir R.

Ophthalmology. 2016 Jan;123(1):51-9. doi: 10.1016/j.ophtha.2015.09.018. Epub 2015 Oct 21.

PMID:
26477842
5.

Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration.

Stepien KE, Rosenfeld PJ, Puliafito CA, Feuer W, Shi W, Al-Attar L, Dubovy SR, Murray TG, Davis JL, Lee WH, Schwartz SG, Smiddy WE, Berrocal AM, Flynn HW Jr.

Retina. 2009 Sep;29(8):1067-73. doi: 10.1097/IAE.0b013e3181b1bb06.

PMID:
19696701
6.

Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.

Landa G, Amde W, Doshi V, Ali A, McGevna L, Gentile RC, Muldoon TO, Walsh JB, Rosen RB.

Ophthalmologica. 2009;223(6):370-5. doi: 10.1159/000227783. Epub 2009 Jul 8.

PMID:
19590252
7.

Comparison of outcomes after switching treatment from intravitreal bevacizumab to ranibizumab in neovascular age-related macular degeneration.

Kent JS, Iordanous Y, Mao A, Powell AM, Kent SS, Sheidow TG.

Can J Ophthalmol. 2012 Apr;47(2):159-64. doi: 10.1016/j.jcjo.2012.01.003.

PMID:
22560422
8.
9.

[Results of an expert survey on VEGF inhibitors in ophthalmology].

Kühn T.

Klin Monbl Augenheilkd. 2011 Jul;228(7):607-12. doi: 10.1055/s-0029-1245827. Epub 2011 Apr 6. German.

PMID:
21472638
10.

[Lucentis versus Avastin--is there a light at the end of the tunnel for age-related macular degeneration patients?].

Waisbourd M, Leibovitch I, Loewenstein A, Yassur Y.

Harefuah. 2008 Jul;147(7):605-6, 662. Hebrew.

PMID:
18814519
11.

A view on new drugs for macular degeneration.

[No authors listed]

Drug Ther Bull. 2007 Jul;45(7):49-52. Review.

PMID:
17718304
12.

[Avastin-Lucentis: off-label and surroundings].

Messori A.

Recenti Prog Med. 2014 Apr;105(4):137-40. doi: 10.1701/1459.16117. Italian.

PMID:
24770536
13.

Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness.

Raftery J, Clegg A, Jones J, Tan SC, Lotery A.

Br J Ophthalmol. 2007 Sep;91(9):1244-6. Epub 2007 Apr 12.

14.

Intravitreal Bevacizumab Versus Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration: Findings from a Cochrane Systematic Review.

Solomon SD, Lindsley KB, Krzystolik MG, Vedula SS, Hawkins BS.

Ophthalmology. 2016 Jan;123(1):70-77.e1. doi: 10.1016/j.ophtha.2015.09.002. Epub 2015 Oct 21. Review.

15.

Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file.

Brechner RJ, Rosenfeld PJ, Babish JD, Caplan S.

Am J Ophthalmol. 2011 May;151(5):887-895.e1. doi: 10.1016/j.ajo.2010.11.017. Epub 2011 Feb 18.

PMID:
21310390
17.

Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, Gonzalez S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK, Kumar G.

Retina. 2006 May-Jun;26(5):495-511.

PMID:
16770255
18.

Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review.

Schmucker C, Ehlken C, Hansen LL, Antes G, Agostini HT, Lelgemann M.

Curr Opin Ophthalmol. 2010 May;21(3):218-26. doi: 10.1097/ICU.0b013e3283386783. Review.

PMID:
20393293
19.

Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients.

Li J, Zhang H, Sun P, Gu F, Liu ZL.

Int J Ophthalmol. 2013 Apr 18;6(2):169-73. doi: 10.3980/j.issn.2222-3959.2013.02.12. Print 2013.

20.

Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration.

Chang TS, Kokame G, Casey R, Prenner J, Feiner L, Anderson N.

Retina. 2009 Oct;29(9):1235-41. doi: 10.1097/IAE.0b013e3181b20eed.

PMID:
19934818

Supplemental Content

Support Center